GlassScriptPhysician profile
Hannah Savely
NPI 1265087464
$12,925.23
in general payments reported to CMS, 2019-2025
29 companies · $4,330 in 2025
The $4,330 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $146 · 2022: $2,086 · 2023: $2,916 · 2024: $3,447 · 2025: $4,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,859 · Education: $835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,858.54 |
| Education | $834.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,999.32 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $1,355.20 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $1,172.73 | 2022-2025 | |
| Janssen Biotech, INC. | $1,087.59 | 2022-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $791.30 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $745.17 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $657.38 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $645.86 | 2022-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $584.16 | 2023-2025 | Dupixent |
| Genzyme Corporation | $459.96 | 2021-2025 | |
| Galderma Laboratories, L.P. | $406.22 | 2024-2025 | Nemluvio |
| Amgen INC. | $365.43 | 2023-2025 | Otezla, Otezla |
| Organon LLC | $219.45 | 2024-2025 | Hadlima, Vtama |
| Pfizer INC. | $219.43 | 2021-2025 | |
| Incyte Corporation | $202.74 | 2021-2025 | Opzelura |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $200.43 | 2023-2025 | Puraply, Novachor, Cygnus Dual |
| Sanofi-Aventis U.S. LLC | $168.99 | 2022-2025 | |
| Kerecis Limited | $133.17 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.41 | 2022-2025 | Spevigo, Cyltezo |
| Mallinckrodt Hospital Products INC. | $98.79 | 2024-2025 | Acthar |
| Arcutis Biotherapeutics, INC. | $50.41 | 2024 | Zoryve |
| Dermavant Sciences, INC. | $47.94 | 2023-2024 | Vtama |
| Mayne Pharma Commercial LLC | $46.15 | 2025 | |
| Biofrontera INC. | $40.03 | 2024-2025 | Ameluz, Rhodoled Xl, Xepi |
| Fresenius Kabi USA, LLC | $39.82 | 2024 | Idacio |
| Nabriva Therapeutics, Plc | $18.22 | 2022 | |
| Genentech USA, INC. | $16.00 | 2022 | |
| Sandoz INC. | $13.78 | 2024 | Hyrimoz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $12.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Savely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.